The Net Clinical Benefit of Rivaroxaban Compared to Low-Molecular-Weight Heparin in the Treatment of Cancer-Associated Thrombosis: Systematic Review and Meta-Analysis

Cancer-associated thrombosis (CAT) carries significant morbidity and mortality. Low-molecular-weight heparin (LMWH) remains the standard of care, with recent systematic studies suggesting the efficacy and safety of rivaroxaban in the treatment of CAT. Uncertainty, however, remains regarding rivaroxa...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Appl Thromb Hemost
Main Authors: Mohamed, Mouhand F. H., ElShafei, Mohamad Nabil, Ahmed, Mohamed Badie, Abdalla, Lina O., Ahmed, Israa, Elzouki, Abdel-Naser, Danjuma, Mohammed ibn-mas’ud
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2021
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7930650/
https://ncbi.nlm.nih.gov/pubmed/33651658
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1076029620940046
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados